Compounded Semaglutide and Compliance: What Changed and What Owners Need to Know

Few service lines have grown as quickly, or drawn as much regulatory attention, as compounded GLP-1 weight-loss programs. What started as a shortage-driven workaround became a core offering for many med spas and wellness practices — and the rules governing who can prescribe, dispense, and market these medications have shifted more than once as supply conditions and federal guidance changed. A program built around last year’s rules can be out of step with this year’s.

Why Compounding Status Matters

Compounded versions of GLP-1 medications are generally permitted only under specific conditions tied to drug shortages declared by federal regulators, or through legitimate patient-specific compounding for documented clinical reasons — not as a general lower-cost alternative to the branded product. As shortage designations change, a compounding pharmacy’s ability to legally supply these medications can change with them, and practices need to stay current rather than assuming today’s supply arrangement is permanent.

The Compliance Layer Specific to These Programs

• A genuine good-faith exam and documented clinical rationale for each patient, not a volume-driven intake process
• Confirmation that your compounding pharmacy partner is properly licensed and operating within current shortage or patient-specific compounding rules
• Ongoing monitoring protocols for patients on these medications, not just an initial prescription with no structured follow-up
• Clear documentation of dosing decisions and any adjustments, tied to actual clinical review
• Marketing claims reviewed carefully — efficacy and safety claims for these medications draw regulatory attention, particularly when compared to branded alternatives

A compounding relationship that was compliant when it started can drift out of compliance as shortage designations and federal guidance change — without anyone at the practice necessarily noticing the shift.

Why This Belongs in the Structure Conversation, Not Just the Clinical One

Because this service line often runs at higher volume and higher margin than traditional aesthetic treatments, it tends to attract more regulatory and payer scrutiny than owners initially expect. The entity structure, physician oversight, and documentation standards that apply to the rest of the practice apply here too — often with less room for error, given how actively this specific category is being watched right now.

If you’re running or considering a compounded medication program and want to confirm your current setup reflects where the rules actually stand today, that’s exactly where we start every engagement.